Guidance

Pneumococcal Conjugate Vaccine (PCV) 4-dose vial presentations - Frequently Asked Questions (FAQs)

Based on current timelines, PCV13 4-dose vials have become available to Gavi countries in 2017 and PCV10 4-dose vials are forecasted to become available in 2018. The availability of PCV10 4-dose vials is pending its prequalification by the World Health Organization, expected in late 2017, and, as the case may be, its local registration. These FAQs give an overview of the characteristics of these two new PCV 4-dose vial presentations, as well as the process of switching presentations and the support provided by Gavi in doing so. If you are interested in switching from your current PCV presentation to one of these new presentations, you will need to submit a request through the Gavi country portal during the annual reporting cycle in May 2017, or if urgent, through a letter to Gavi.

Languages

  • English

Publication year

2017

Publisher

Gavi

Type

Guidance

Categories

  • Vaccines & delivery devices

Diseases

  • Pneumococcal disease

Topic references

EPI-CORE-PNEUMO

TitleAuthorYearTypeLanguage
Characteristics of different presentations of Pneumococcal Conjugate VaccinesWorld Health Organization (WHO)2017Poster/infographicEnglish
Pneumococcal Conjugate Vaccine (PCV) 4-dose vial presentations - Frequently Asked Questions (FAQs)Gavi, the Vaccine Alliance2017GuidanceEnglish
Pneumococcal Vaccine: Handling the change in product manufacturer and presentationWorld Health Organization (WHO)2017GuidancePortuguese

Added by: Géraldine Nemrod

Added on: 2020-10-28 01:55:20

Hits: 1242

Uploaded file

PCV4-dosevials-FAQs2017_20032017.pdf

Click to Download